NCT05796362View on ClinicalTrials.gov

A Single-Dose, Three-Way, Three-Sequence, Crossover BA Study of Azithromycin Oleogel

PHASE1RecruitingINTERVENTIONAL
Enrollment

21

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

October 31, 2025

Study Completion Date

October 31, 2025

Conditions
Infectious DiseaseDrug EffectClinical Infection
Interventions
DRUG

Azithromycin Oleogel (Oral and Rectal)

"Exploratory study of a novel oleogel dosage form of Azithromycin (Zithromax)"

Trial Locations (1)

02115

RECRUITING

Brigham and Women's Hospital, Boston

All Listed Sponsors
collaborator

Bill and Melinda Gates Foundation

OTHER

lead

Brigham and Women's Hospital

OTHER